X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14) 14
index medicus (14) 14
hematology (12) 12
female (10) 10
male (10) 10
adult (9) 9
middle aged (9) 9
aged (8) 8
chronic myeloid leukemia (7) 7
oncology (6) 6
aged, 80 and over (5) 5
antineoplastic agents - therapeutic use (5) 5
chronic myelogenous leukemia (5) 5
dasatinib (5) 5
imatinib mesylate (5) 5
leukemia (5) 5
piperazines - therapeutic use (5) 5
pyrimidines - therapeutic use (5) 5
adolescent (4) 4
imatinib (4) 4
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (4) 4
leukemia, myeloid, chronic-phase - drug therapy (4) 4
prognosis (4) 4
young adult (4) 4
abridged index medicus (3) 3
benzamides (3) 3
chronic-phase (3) 3
follow-up (3) 3
follow-up studies (3) 3
hemic and lymphatic diseases (3) 3
interferon-alpha (3) 3
leukemia, myeloid, chronic-phase - mortality (3) 3
mutation (3) 3
primary myelofibrosis - diagnosis (3) 3
protein kinase inhibitors - therapeutic use (3) 3
resistance (3) 3
retrospective studies (3) 3
survival analysis (3) 3
thiazoles - therapeutic use (3) 3
treatment outcome (3) 3
tyrosine kinase inhibitors (3) 3
analysis (2) 2
antineoplastic agents - pharmacology (2) 2
bcr-abl (2) 2
benzamides - therapeutic use (2) 2
cancer (2) 2
cytogenetic analysis (2) 2
disease-free survival (2) 2
early molecular response (2) 2
elderly (2) 2
european-leukemianet (2) 2
hypertension (2) 2
interferon (2) 2
intolerance (2) 2
janus kinase 2 - genetics (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - genetics (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - mortality (2) 2
leukemia, myeloid, chronic-phase - genetics (2) 2
leukemia, myeloid, chronic-phase - pathology (2) 2
molecular response (2) 2
multivariate analysis (2) 2
myelofibrosis (2) 2
myeloproliferative neoplasms (2) 2
nilotinib (2) 2
polycythemia vera - complications (2) 2
ponatinib (2) 2
primary myelofibrosis - genetics (2) 2
primary myelofibrosis - mortality (2) 2
pyrimidines - adverse effects (2) 2
risk (2) 2
spain (2) 2
survival (2) 2
therapy (2) 2
time factors (2) 2
aberrant methylation (1) 1
achievement (1) 1
activities of daily living (1) 1
acute myeloid-leukemia (1) 1
age (1) 1
aged patients (1) 1
ageism (1) 1
aniline compounds - administration & dosage (1) 1
aniline compounds - adverse effects (1) 1
aniline compounds - therapeutic use (1) 1
antineoplastic agents - adverse effects (1) 1
antiviral agents (1) 1
articles (1) 1
asxl1 (1) 1
base-excision-repair (1) 1
basic education (1) 1
bcr-abl1 transcript levels (1) 1
bios3 (1) 1
blast crisis - prevention & control (1) 1
blood cell count (1) 1
bosutinib (1) 1
budget impact (1) 1
cadherins - genetics (1) 1
cadherins - metabolism (1) 1
calcium - metabolism (1) 1
calr (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 24, pp. 2260 - 2270
Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2015, Volume 90, Issue 5, pp. 429 - 433
Journal Article
Haematologica, ISSN 0390-6078, 2017, Volume 102, Issue 1, pp. 103 - 109
Journal Article
Journal Article
Journal of geriatric oncology, ISSN 1879-4068, 04/2019
To explore the preferences of Spanish healthcare professionals (haematologists and hospital pharmacists) for the treatment selection of active Chronic... 
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 10/2015, Volume 56, Issue 10, pp. 2973 - 2974
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 152 - 152
Abstract Background: The randomized, phase 3 DASISION trial demonstrated improved efficacy with dasatinib compared with imatinib in treatment-naïve CML-CP... 
Journal Article
European Journal of Haematology, ISSN 0902-4441, 10/2016, Volume 97, Issue 4, pp. 331 - 335
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 1675 - 1675
Abstract Abstract 1675 Background: In the randomized phase 3 DASISION trial in patients (pts) with newly diagnosed CML-CP, dasatinib 100 mg once daily (QD)... 
Journal Article
Leukemia Research, ISSN 0145-2126, 2011, Volume 35, Issue 9, pp. 1184 - 1187
Journal Article